Skip to main content

Table 3 Liver-Specific characteristics of HIV-infected participants by HBV infection status (N = 2419)

From: Characteristics and outcomes of antiretroviral-treated HIV-HBV co-infected patients in Canada

Clinical CharacteristicsHIV N = 2220HIV-HBV Co-Infected N = 199p valuea
Hepatitis C co-infection520 (23)61 (31)0.02
Baseline AST (IU/L)29 (23–41)36 (26–62)< 0.0001
Baseline AST category
 Normal (10–40 IU/L)1649 (74)120 (60)< 0.0001
 Elevated (> 40 IU/L)571 (26)79 (40)
End of follow-up AST25 (20–33)26 (20–38)0.14
End of follow-up AST category
 Normal (10–40 IU/L)1855 (84)152 (76)0.01
 Elevated (> 40 IU/L)365 (17)47 (24)
Baseline APRI0.37 (0.27–0.59)0.50 (0.35–1.04)< 0.0001
Baseline APRI Fibrosis category
  ≤ 0.5 (minimal)1501 (68)99 (50)< 0.0001b
 0.51–1.49 (moderate)593 (27)68 (34)
 1.50–1.99 (significant)34 (2)8 (4)
  ≥ 2.0 (advanced/cirrhosis)92 (4)24 (12)
End of follow-up APRI0.30 (0.22–0.43)0.32 (0.23–0.56)0.03
End of follow-up APRI Fibrosis category
  ≤ 0.5 (minimal)1831 (82)145 (73)0.005b
 0.51–1.49 (moderate)302 (14)39 (20)
 1.50–1.99 (significant)24 (1)3 (2)
  ≥ 2.0 (advanced/cirrhosis)63 (3)12 (6)
  1. AST aspartate aminotransferase, APRI aspartate aminotransferase to platelet ratio index, VS virological suppression, FARVDT first naïve ARV date
  2. aData shown are frequencies and proportions for categorical variables and median and interquartile ranges for continuous variables. p values for continuous variables were calculated using chi-square or Fisher exact tests and for continuous variables were calculated using Wilcoxon’s Rank Sum tests
  3. bp values were calculated using Kruskal-Wallis rank tests